KR20120018761A - 섬유증을 치료하기 위한 방법 및 ｐｉ-3 키나제 억제제의 조성물 - Google Patents

섬유증을 치료하기 위한 방법 및 ｐｉ-3 키나제 억제제의 조성물 Download PDF

Info

Publication number
KR20120018761A
KR20120018761A KR1020117026616A KR20117026616A KR20120018761A KR 20120018761 A KR20120018761 A KR 20120018761A KR 1020117026616 A KR1020117026616 A KR 1020117026616A KR 20117026616 A KR20117026616 A KR 20117026616A KR 20120018761 A KR20120018761 A KR 20120018761A
Authority
KR
South Korea
Prior art keywords
fibrosis
kinase
kinase inhibitor
pulmonary fibrosis
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020117026616A
Other languages
English (en)
Korean (ko)
Inventor
윌리암 하디
로버트 커크먼
Original Assignee
온코타이레온, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 온코타이레온, 인코포레이티드 filed Critical 온코타이레온, 인코포레이티드
Publication of KR20120018761A publication Critical patent/KR20120018761A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020117026616A 2009-04-09 2010-04-08 섬유증을 치료하기 위한 방법 및 ｐｉ-3 키나제 억제제의 조성물 Ceased KR20120018761A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US16790509P 2009-04-09 2009-04-09
US61/167,905 2009-04-09
US23574009P 2009-08-21 2009-08-21
US61/235,740 2009-08-21

Publications (1)

Publication Number Publication Date
KR20120018761A true KR20120018761A (ko) 2012-03-05

Family

ID=42936877

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020117026616A Ceased KR20120018761A (ko) 2009-04-09 2010-04-08 섬유증을 치료하기 위한 방법 및 ｐｉ-3 키나제 억제제의 조성물

Country Status (10)

Country Link
US (1) US20120046333A1 (enExample)
EP (1) EP2416771A4 (enExample)
JP (1) JP2012523429A (enExample)
KR (1) KR20120018761A (enExample)
CN (1) CN102395363A (enExample)
AU (1) AU2010234360A1 (enExample)
BR (1) BRPI1015940A2 (enExample)
CA (1) CA2754343A1 (enExample)
MX (1) MX2011010631A (enExample)
WO (1) WO2010118250A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102727478A (zh) * 2012-06-14 2012-10-17 合肥博太医药生物技术发展有限公司 视黄酸及其衍生物在制备防治肾纤维化药物中的应用
TWI687220B (zh) 2013-03-01 2020-03-11 美商英塞特控股公司 吡唑并嘧啶衍生物治療PI3Kδ相關病症之用途
US20190269675A1 (en) 2014-01-28 2019-09-05 Buck Institute for Research and Aging Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents
EP3099380B1 (en) 2014-01-28 2021-08-11 Buck Institute for Research on Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
WO2015116735A1 (en) 2014-01-28 2015-08-06 Mayo Foundation For Medical Education And Research Methods and combinations for killing senescent cells and for treating senescence-associated diseases and disorders
CN110917351A (zh) * 2018-09-20 2020-03-27 华中科技大学同济医学院附属同济医院 Mbd2抑制剂在预防和治疗纤维化疾病中的用途
JP2022065212A (ja) * 2019-02-28 2022-04-27 国立大学法人京都大学 組織線維化による疾患の予防又は治療のための医薬
WO2020201073A1 (en) * 2019-03-29 2020-10-08 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of keloid, hypertrophic scars and/or hyperpigmentation disorders
WO2022125784A1 (en) * 2020-12-10 2022-06-16 Children's Hospital Medical Center Enhanced nanoparticle delivery systems

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004075917A1 (ja) * 2003-02-28 2004-09-10 Toudai Tlo, Ltd. 器官または組織の線維化抑制剤
JP5371426B2 (ja) * 2004-07-09 2013-12-18 プロルックス ファーマシューティカルズ コープ． ワートマニン類似体及び化学療法薬と組み合わせた同一物を使用する方法
US20090306020A1 (en) * 2005-05-27 2009-12-10 Bayer Healthcare Ag Combination therapy comprising diaryl ureas for treating diseases
CN101180055A (zh) * 2005-05-27 2008-05-14 拜耳医药保健股份公司 用于治疗疾病的包含二芳基脲的组合治疗
EP1965790B1 (en) * 2005-12-30 2011-12-07 Arizona Board of Regents, Acting on Behalf of The University of Arizona Metabolites of wortmannin analogs and methods of using the same
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use

Also Published As

Publication number Publication date
JP2012523429A (ja) 2012-10-04
CA2754343A1 (en) 2010-10-14
BRPI1015940A2 (pt) 2016-04-19
EP2416771A4 (en) 2012-10-31
US20120046333A1 (en) 2012-02-23
WO2010118250A3 (en) 2011-03-31
EP2416771A2 (en) 2012-02-15
AU2010234360A1 (en) 2011-09-29
MX2011010631A (es) 2012-01-20
WO2010118250A2 (en) 2010-10-14
CN102395363A (zh) 2012-03-28

Similar Documents

Publication Publication Date Title
KR20120018761A (ko) 섬유증을 치료하기 위한 방법 및 ｐｉ-3 키나제 억제제의 조성물
McCollum et al. Angiotensin-(1–7) attenuates angiotensin II-induced cardiac remodeling associated with upregulation of dual-specificity phosphatase 1
US20190175623A1 (en) Chemical compounds for treating atherosclerosis by stabilizing atherosclerotic plaques or delaying atherogenesis
TWI532480B (zh) 以斑馬魚模組進行藥物篩選之方法及篩選所得藥物
JP2018521120A (ja) 翼状片を治療するための組成物及び方法
CN110461862A (zh) 用于治疗由衰老细胞介导的病症和用于治疗癌症的基于肽的蛋白酶体抑制剂
EP3352759A1 (en) Treatment of neurodegenerative diseases
CN105535001B (zh) 红景天苷在制备治疗糖尿病足的药物中的应用
CN112469411B (zh) 供在由衰老细胞引起或介导的状况的临床管理中使用和用于治疗癌症的作为Bcl家族拮抗剂的氨基膦酸酯
JP2023518375A (ja) 治療方法
JP2010509247A (ja) Ａｃａｔ阻害剤及び線維症の予防又は治療におけるその使用
KR20230004650A (ko) 호흡기 병태를 치료하기 위한 trpc6의 억제제
JP6700312B2 (ja) 組織再生及び衰えた組織機能の回復を刺激するための作用物質としてのジカルボン酸のビスアミド誘導体
Huang et al. AZD6738 decreases intraocular pressure and inhibits fibrotic response in trabecular meshwork through CHK1/P53 pathway
JP2019182836A (ja) 糖尿病性腎症の予防薬及び／又は治療薬
US20210379078A1 (en) Killing Senescent Cells And Treating Senescence-Associated Conditions Using A Bcl Inhibitor And An Mcl-1 Inhibitor
US20210069189A1 (en) Treatment of neurodegenerative diseases
EP3548504A1 (en) Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
WO2018137701A1 (zh) 靶向cxcr7的药物组合物和方法
WO2016085981A1 (en) Method of inhibiting or treating fibrosis
US10745429B2 (en) Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
US20150342913A1 (en) Method of inhibiting or treating fibrosis
TWI876411B (zh) 治療周邊動脈疾病的用途
WO2014065370A1 (ja) 肺高血圧症治療剤
WO2025135087A1 (ja) 慢性移植片対宿主病における眼合併症の予防治療用医薬組成物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20111108

Patent event code: PA01051R01D

Comment text: International Patent Application

A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20111109

Comment text: Request for Examination of Application

PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20130612

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20130826

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20130612

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I